Literature DB >> 31887831

[China cholesterol education program (CCEP) expert advice for the management of dyslipidaemias to reduce cardiovascular risk (2019)].

.   

Abstract

The prevalence of dyslipidemia in Chinese adult is increasing dramatically, which poses a severe challenge to the prevention and treatment of atherosclerotic cardiovascular diseases. In recent years, a series of new research results have been published, providing a lot of new information for the management strategy of dyslipidemia. In order to apply these new research results to clinical practice for the further prevention and treatment of dyslipidemia more reasonably and effectively, the China Cholesterol Education Program (CCEP) Working Committee organized joint expert meeting and revised the "Expert Advice on Prevention and Treatment of Dyslipidemia in China Cholesterol Education Program 2014", in which a new classification standard for cardiovascular risk stratification has been proposed, and the target value of lipid-lowering therapy has been updated.

Entities:  

Keywords:  Cardiovascular event; Dyslipidemia; Practice guideline

Mesh:

Substances:

Year:  2020        PMID: 31887831     DOI: 10.3760/cma.j.issn.0578-1426.2020.01.003

Source DB:  PubMed          Journal:  Zhonghua Nei Ke Za Zhi        ISSN: 0578-1426


  4 in total

1.  Trends of Hypercholesterolemia Change in Shenzhen, China During 1997-2018.

Authors:  Ke Peng; Weicong Cai; Xiaoying Liu; Yishu Liu; Yu Shi; Jessica Gong; Lin Lei; Ji Peng; Yuxin Xie; Honglei Zhao; Lei Si; Menglu Ouyang
Journal:  Front Public Health       Date:  2022-05-02

2.  Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China.

Authors:  Lei Bi; Jiayi Yi; Chaoqun Wu; Shuang Hu; Xingyi Zhang; Jiapeng Lu; Jiamin Liu; Haibo Zhang; Yang Yang; Jianlan Cui; Wei Xu; Lijuan Song; Yuanlin Guo; Xi Li; Xin Zheng
Journal:  Front Cardiovasc Med       Date:  2022-03-28

3.  Non-fasting Changes in Blood Lipids After Three Daily Meals Within a Day in Chinese Inpatients With Cardiovascular Diseases.

Authors:  Yangrong Tan; Qiuzhen Lin; Jin Xu; Liyuan Zhu; Liling Guo; Yingying Xie; Xiao Du; Shilan Zhang; Tie Wen; Ling Liu
Journal:  Front Cardiovasc Med       Date:  2022-04-12

Review 4.  Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients With Acute Coronary Syndrome.

Authors:  Qinqin Wang; Chun Liang
Journal:  J Cardiovasc Pharmacol       Date:  2020-12       Impact factor: 3.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.